|
業務類別
|
Biotechnology |
|
業務概覽
|
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis. |
| 公司地址
| 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182 |
| 電話號碼
| +1 703 506-9460 |
| 傳真號碼
| +1 703 506-9471 |
| 公司網頁
| https://www.cel-sci.com |
| 員工數量
| 57 |
| Dr. Daniel H. Zimmerman, PhD |
Senior Vice President, Research, Cellular Immunology |
-- |
09/04/2025 |
| Mr. Geert R. Kersten, Esq. |
Director, Chief Executive Officer, Principal Accounting Officer and Treasurer |
美元 644.09K |
02/07/2026 |
| Mr. John Cipriano |
Senior Vice President, Regulatory Affairs |
美元 249.56K |
02/07/2026 |
| Ms. Patricia B. Prichep |
Chief Financial and Operations Officer and Corporate Secretary |
美元 289.19K |
02/07/2026 |
| Dr. Eyal Talor, PhD |
Chief Scientific Officer |
美元 349.61K |
02/07/2026 |
|
|
| Mr. Geert R. Kersten, Esq. |
Director, Chief Executive Officer, Principal Accounting Officer and Treasurer |
02/07/2026 |
| Mr. Robert E. Watson |
Chairman of the Board |
02/07/2026 |
| Mr. Bruno Baillavoine |
Independent Director |
02/07/2026 |
|
|
|
|
